NASDAQ:GRI
GRI Bio, Inc.
GRI Bio, Inc. reported net income of −$12.0M in fiscal 2025. Free cash flow was −$10.2M, and the diluted share count rose 1399.3%.Summary generated from GRI Bio, Inc.'s SEC filings. Latest annual report filed Jan 30, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−238.2%
Debt / equityn/a
Free cash flow−$10.2M
FCF marginn/a
Share count change+1399.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | n/a | n/a | n/a | n/a |
| Operating income | −9 | −2 | −11 | −8 | −12 |
| Net income | −9 | −3 | −13 | −8 | −12 |
| Free cash flow | −8 | −1 | −9 | −9 | −10 |
Recent filings
- DEF 14AProxy statement
Sep 28, 2026 - 8-KRegulation FD disclosure
Sep 8, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KOther events
Jun 18, 2026 - 8-KResults of operations and financial condition
May 14, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 13, 2026 - 8-KResults of operations and financial condition
Feb 4, 2026 - 10-KAnnual report for the fiscal year ended Dec 31, 2025
Jan 30, 2026